TY  - GEN
AU  - Tolar,Jakub
AU  - Deeg,H Joachim
AU  - Arai,Sally
AU  - Horwitz,Mitchell
AU  - Antin,Joseph H
AU  - McCarty,John M
AU  - Adams,Roberta H
AU  - Ewell,Marian
AU  - Leifer,Eric S
AU  - Gersten,Iris D
AU  - Carter,Shelly L
AU  - Horowitz,Mary M
AU  - Nakamura,Ryotaro
AU  - Pulsipher,Michael A
AU  - Difronzo,Nancy L
AU  - Confer,Dennis L
AU  - Eapen,Mary
AU  - Anderlini,Paolo
TI  - Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels
SN  - 1523-6536
PY  - 2013///0503
KW  - Acute Disease
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Anemia, Aplastic
KW  - mortality
KW  - Antilymphocyte Serum
KW  - administration & dosage
KW  - Antineoplastic Agents
KW  - Bone Marrow Transplantation
KW  - Child
KW  - Cyclophosphamide
KW  - Drug Administration Schedule
KW  - Drug Dosage Calculations
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Survival Rate
KW  - Transplantation Conditioning
KW  - Unrelated Donors
KW  - Vidarabine
KW  - Whole-Body Irradiation
KW  - adverse effects
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1016/j.bbmt.2012.04.014
ER  -